Clareo Health | Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
20–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy volunteers for brain imaging:
males or females, age 20 - 55 years
assessment of the brain MRI as "normal (age-appropriate)"
absence of any sign of CNS disease, no co-medi cation Patients for brain imaging
males or females, age 20 - 55 years
patients with previously diagnosed MS, presenting with acute relapse, without any current immunomodulating therapy for MS ("drug-naïve"), or patients presenting with first clinical episode suggestive of demyelinating disease (Clinically Isolated Syndrome, CIS)
patients with previously diagnosed MS, presenting with acute relapse, receiving currently immunomodulatory therapy exclusively with interferon β
Any disease, condition, or concomitant medications that significantly compromises the function of the body systems and could result in excessive accumulation, impaired metabolism, altered excretion of the radiotracer, or might interfere with the conduct of the study or interpretation of the results
other forms of diseases with neuroinflammatory components
